Recent Updates
Recently added Catalysts
OKYO Positive Sentiment

OKYO Pharma Announces Purchase of Shares by Director

Thursday, July 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: OKYO Pharma Limited announced that Non-Executive Director John Brancaccio purchased 5,000 shares at $1.48 each, increasing his total holdings to 35,201 shares. The company is preparing to launch a Phase 3 clinical trial for its investigational therapy targeting neuropathic corneal pain. This trial will involve around 111 patients and is set to begin in the latter half of the year.
Price reaction · baseline $1.48 (2026-07-23T15:58:00.000Z) · hit during market hours · clean, no other OKYO news in the window
day 0 close · peak
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Director's purchase indicates confidence in the company's future.
  • OKYO Pharma is advancing towards a Phase 3 clinical trial.
  • The share price is perceived as attractive at $1.48.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+14%
120-day peak, hindsight
Typical move
5.1%
average across 4 past catalysts
Lead asset
Urcosimod is a preservative-free product; supplied in unit dose ampoules; administered QID for 12-weeks
Phase 3 · Neuropathic Corneal Pain

Full Press Release Details

LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares.

About OKYOPharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
For further information, please visitwww.okyopharma.com.

For further inquiries:

OKYO Pharma LtdPaul SpencerBusiness Development and Investor Relations+44 (0) 207 495 2379Email:info@okyopharma.com

Frequently Asked Questions

Who purchased shares in OKYO Pharma?

Non-Executive Director John Brancaccio purchased 5,000 shares.

What is the share price at which the purchase was made?

The shares were purchased at $1.48 each.

What clinical trial is OKYO Pharma planning?

OKYO Pharma plans to initiate a Phase 3 clinical trial for neuropathic corneal pain.

How many patients will be enrolled in the trial?

Approximately 111 patients will be enrolled in the trial.

ShareAdd on Google
Tags: OKYO OKYO Pharma John Brancaccio share purchase neuropathic corneal pain Phase 3 trial
Last updated: Jul 23, 2026

Biotech snapshot

Lead asset
Urcosimod is a preservative-free product; supplied in unit dose ampoules; administered QID for 12-weeksPhase 3
Neuropathic Corneal Pain →

Catalyst track record

+14%
best trade around OKYO's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for OKYO.

See every catalyst's timing & PoA →